07:12 AM EDT, 10/16/2026 (MT Newswires) -- Eli Lilly's (LLY.SW) weight loss and type 2 diabetes pill Foundayo was recommended for approval by the European Medicines Agency's Committee for Medicinal Products for Human Use. The recommendation for weight loss was backed by the results of two studies, where participants lost 5% to 11% of body weight with Foundayo, compared with 2% to 2.5% in the placebo group, according to a Friday note. For type 2 diabetes, the once-daily drug was tested across four studies, where Foundayo reduced HbA1c by 1.2 percentage points to 1.9 percentage points, compared with reductions of 0.4 percentage points to 0.8 percentage points with placebo. The drug is subject to final approval from the European Commission.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.